Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Tilsætning af navlestrengsblod-afledte mesenkymale stromaceller til Ruxolitinib til behandling af steroid-refraktær akut graft versus værtssygdom

21. september 2026 opdateret af: M.D. Anderson Cancer Center

En randomiseret kontrolleret pilotundersøgelse af to doser navlestrengsblod-afledte mesenkymale stromaceller kombineret med ruxolitinib versus ruxolitinib alene til behandling af steroid-refraktær akut graft versus værtssygdom

This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid therapy (steroid-refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. cb-MSCs are a type of tissue helper cell that can be removed from donated umbilical cord blood tissue and grown into many different cell types that can be used to treat cancer and other disease, such as graft versus host disease. This trial aims to learn if adding cb-MSCs to ruxolitinib may help control steroid-refractory acute graft versus host disease.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

PRIMARY OBJECTIVE:

I. To estimate between-arm differences (Arm 3 versus [vs] Arm 1, and Arm 2 vs Arm 1) for each of the 28-day co-primary outcome probabilities.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM 1: Patients receive ruxolitinib orally (PO) twice daily (BID) for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.

ARM 2: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs intravenously (IV) for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.

ARM 3: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.

After completion of study treatment, patients are followed up on day 28 and then for up to 6 months.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

24

Fase

  • Tidlig fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • M D Anderson Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Partow Kebriaei, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år til 80 år (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Participants between the ages of 12 years and 80 years (inclusive).
  2. Steroid refractory grades II-IV acute GVHD of the Lower GI tract or Liver (including those developing these manifestations after previous acute GVHD of skin) secondary to allogeneic HCT or donor lymphocyte infusion. (Grading, see Appendix I) GVHD with: No improvement after treatment with methylprednisolone at ≥ 2.0 mg/kg/day or equivalent for minimum 7 days, or progressive symptoms after minimum 3 days, or a flare in acute GVHD while on systemic steroids. Participants must have had a biopsy that suggests GVHD; a repeat biopsy to enroll on the study is not necessary.
  3. Karnofsky/Lansky Performance score of at least 30 at the time of study entry.
  4. Participants who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception
  5. Participants (or legal representative where appropriate) must be capable of providing written informed consent, and assent if indicated.

Exclusion Criteria:

  1. De novo chronic GVHD
  2. Isolated acute GVHD of skin
  3. Secondary systemic therapy for acute GVHD ruxolitinib greater than 96 hours before initiation of therapy.
  4. Primary treatment with agents other than alpha-1 antitrypsin (AAT) glucocorticoids and ruxolitinib.
  5. Participants with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
  6. Adult and pediatric patients with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.
  7. Participants with significant supplemental oxygen requirement defined as >6 L oxygen by nasal cannula.
  8. Participants with known allergy to bovine or porcine products.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Arm 1 (ruxolitinib)

Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.

Given PO

Andre navne:
  • Jakafi
  • INCB-18424
  • INCB18424
  • Oral JAK-hæmmer INCB18424
Eksperimentel: Arm 2 (ruxolitinib, lower dose ds-MSCs)

Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.

Given PO

Andre navne:
  • Jakafi
  • INCB-18424
  • INCB18424
  • Oral JAK-hæmmer INCB18424

Given ds-MSCs IV

Andre navne:
  • Celleterapi
Eksperimentel: Arm 3 (ruxolitinib, higher dose ds-MSCs)

Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.

Given PO

Andre navne:
  • Jakafi
  • INCB-18424
  • INCB18424
  • Oral JAK-hæmmer INCB18424

Given ds-MSCs IV

Andre navne:
  • Celleterapi

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Død af enhver årsag
Tidsramme: Inden for 28 dage fra start af aktiv undersøgelsesbehandling
Inden for 28 dage fra start af aktiv undersøgelsesbehandling
Forekomst af uønskede hændelser
Tidsramme: Inden for 28 dage fra start af aktiv undersøgelsesbehandling
Inden for 28 dage fra start af aktiv undersøgelsesbehandling
Response
Tidsramme: At day 28 from start of therapy on study

Will compare the patient's 28-day graft versus host disease (GVHD) status to the patient's baseline GVHD status when steroid refractory acute GVHD was diagnosed.

At day 28 from start of therapy on study

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Forekomst af fuldstændig respons for hvert organ
Tidsramme: Op til 6 måneder
Op til 6 måneder
Forekomst af meget god delvis respons for hvert organ
Tidsramme: Op til 6 måneder
Op til 6 måneder
Forekomst af delvis respons for hvert organ
Tidsramme: Op til 6 måneder
Op til 6 måneder
Holdbarhed af organrespons
Tidsramme: Op til 6 måneder
Op til 6 måneder
Kumulativ forekomst af ikke-tilbagefaldsdødelighed (NRM)
Tidsramme: 6 måneder efter behandling
6 måneder efter behandling
Kumulativ forekomst af tilbagefald/progression af den primære sygdom
Tidsramme: Ved 6 måneder
Ved 6 måneder
Samlet overlevelse
Tidsramme: Fra indskrivning til død uanset årsag, vurderet til 6 måneder
Fra indskrivning til død uanset årsag, vurderet til 6 måneder
Sygdomsfri overlevelse
Tidsramme: Fra indskrivning til død af enhver årsag eller tilbagefald/progression af den primære sygdom, vurderet efter 6 måneder
Fra indskrivning til død af enhver årsag eller tilbagefald/progression af den primære sygdom, vurderet efter 6 måneder
Forekomst af enhver grad af cytokinfrigivelse
Tidsramme: Op til 28 dage efter afslutning af sidste MSC-infusionsundersøgelseslægemiddel
Op til 28 dage efter afslutning af sidste MSC-infusionsundersøgelseslægemiddel
Forekomst af enhver infusionstoksicitet
Tidsramme: Inden for 24 timer efter hver navlestrengsblod-MSC-infusion
Inden for 24 timer efter hver navlestrengsblod-MSC-infusion
Graft versus host disease status
Tidsramme: At days 7, 14, 21 and 28 post treatment

Will assess complete response (CR), very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease (PD).

At days 7, 14, 21 and 28 post treatment
Proportion of response
Tidsramme: At days 7, 14, 21 and 28 post treatment

Will assess proportion of patients with CR, PR, VGPR, and no-response (NR). The event NR is defined as stable disease, mixed response, disease progression, OR initiation of additional systemic (second-line) GVHD therapies.

At days 7, 14, 21 and 28 post treatment
Time to complete response
Tidsramme: Up to 6 months

Will be estimated by the method of Kaplan and Meier.

Up to 6 months
Time to very good partial response
Tidsramme: Up to 6 months

Will be estimated by the method of Kaplan and Meier.

Up to 6 months
Time to partial response
Tidsramme: Up to 6 months

Will be estimated by the method of Kaplan and Meier.

Up to 6 months
Graft versus host disease-free survival
Tidsramme: At 6 months

Patients alive, free of active acute or chronic GVHD, and without other systemic agents (or escalation of steroids to >= 2.5 mg/kg/day of prednisone [or methylprednisolone equivalent of 2 mg/kg/day]) added for treatment of GVHD will be considered successes for this endpoint

At 6 months
Incidence of chronic graft versus host disease
Tidsramme: At 6 months after first mesenchymal stromal cells (MSC) infusion

Chronic GVHD is defined per National Institutes of Health Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) is considered an event for this endpoint. Organ involvement and maximum severity will also be described at six months.

At 6 months after first mesenchymal stromal cells (MSC) infusion
Incidence of systemic infections
Tidsramme: 28 days after last study drug

The incidence of grade 2 to 3 systemic infections occurring from study treatment until 28 days after last study drug will be described using standard Common Terminology Criteria for Adverse Events (CTCAE) criteria. Infections will be recorded by site of disease, date of onset, and severity.

28 days after last study drug
Incidence of toxicities
Tidsramme: Up to 28 days after completing last MSC infusion study drug

The incidence of grade 3-5 treatment-emergent adverse events (per CTCAE version 5.0) that occur through 28 days after completing last MSC infusion study drug will be described.

Up to 28 days after completing last MSC infusion study drug

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cytokine biomarker analysis (optional)
Tidsramme: Up to 6 months

Will use cytokine biomarker assays to predict response to therapy.

Up to 6 months
Fecal samples analysis (optional)
Tidsramme: Up to 6 months

Will use fecal samples to assess microbiome and potential predictor for response to therapy.

Up to 6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Partow Kebriaei, MD, M.D. Anderson Cancer Center

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. februar 2021

Primær færdiggørelse (Anslået)

31. marts 2032

Studieafslutning (Anslået)

31. marts 2032

Datoer for studieregistrering

Først indsendt

3. februar 2021

Først indsendt, der opfyldte QC-kriterier

3. februar 2021

Først opslået (Faktiske)

8. februar 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2019-1122
  • 2019-1122 (Anden identifikator: M D Anderson Cancer Center)
  • NCI-2020-13889 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • P01CA148600 (U.S. NIH-bevilling/kontrakt)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .